Cited by 169Gut microbiota and healthLiver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Intestinal microbiota and nonalcoholic steatohepatitis

Open access

Brandl, Katharina, Schnabl, Bernd·2017·Current Opinion in Gastroenterology

DOI 10.1097/mog.0000000000000349PMC PMC5662009

Open this paper in CoChat — free account

Abstract

PURPOSE OF REVIEW: Nonalcoholic fatty liver disease (NAFLD) is a liver disease with high prevalence in western countries. Progression from NAFLD to nonalcoholic steatohepatitis (NASH) occurs in 10-20%. NASH pathogenesis is multifactorial including genetic and environmental factors. The gut microbiota is involved in disease progression and its role is complex. RECENT FINDINGS: NASH is associated with changes in the intestinal microbiota, although findings in recent studies are inconsistent. Dysbiosis can trigger intestinal inflammation and impair the gut barrier. Microbial products can now reach the liver, induce hepatic inflammation and contribute to NAFLD and NASH progression. As the gut microbiota is also involved in the regulation of metabolic pathways, metabolomic approaches identified unique metabolomic profiles in patients with NASH. Altered metabolite patterns can serve as biomarkers, whereas specific metabolites (such as ethanol) have been linked with disease progression. Modifying metabolic profiles might serve as new therapeutic microbiome-based approaches. SUMMARY: In this review, we will highlight findings from the recent literature important to the gut-liver axis. We will predominantly focus on human studies with NASH.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/mog.0000000000000349

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Diet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
Human gut microbiome viewed across age and geography
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012) · Nature · doi:10.1038/nature11053 · Cited by 7,815
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,820
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans
Sender, R., Fuchs, S., & Milo, R. (2016) · Cell · doi:10.1016/j.cell.2016.01.013 · Cited by 2,050
Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH
Zhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota
Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483

Show all 42 references

Sorted by citations

Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Aron‐Wisnewsky, J., Vigliotti, C., Witjes, J. J., Le, P. T., Holleboom, A. G., Verheij, J., Nieuwdorp, M., & Clément, K. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0269-9 · Cited by 1,132
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
NAFLD as a driver of chronic kidney disease
Byrne, C. D., & Targher, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.013 · Cited by 449
RETRACTED ARTICLE: Role of the gut microbiome in chronic diseases: a narrative review
Vijay, A., & Valdes, A. M. (2022) · European Journal of Clinical Nutrition · doi:10.1038/s41430-021-00991-6 · Cited by 361
Retracted
Adaptive immunity: an emerging player in the progression of NAFLD
Sutti, S., & Albano, E. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0210-2 · Cited by 374
Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
Febbraio, M. A., Reibe, S., Shalapour, S., Ooi, G., Watt, M. J., & Karin, M. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.012 · Cited by 250
Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?
Aron‐Wisnewsky, J., Warmbrunn, M. V., Nieuwdorp, M., & Clément, K. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.049 · Cited by 252
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Intestinal Barrier Function–Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota
Cui, Y., Wang, Q., Chang, R., Zhou, X., & Xu, C. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b00080 · Cited by 220
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
Gutiérrez‐Cuevas, J., Santos, A., & Armendáriz‐Borunda, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111629 · Cited by 227
An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
Pei, K., Gui, T., Kan, D., Feng, H., Jin, Y., Yang, Y., Zhang, Q., Du, Z., Gai, Z., Wu, J., et al. (2020) · BioMed Research International · doi:10.1155/2020/4020249 · Cited by 209
Management of non-alcoholic fatty liver disease
Petroni, M. L., Brodosi, L., Bugianesi, E., & Marchesini, G. (2021) · BMJ · doi:10.1136/bmj.m4747 · Cited by 193
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Dewidar, B., KAHL, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 167
Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial
Bomhof, M. R., Parnell, J. A., Ramay, H. R., Crotty, P., Rioux, K. P., Probert, C. S., Jayakumar, S., Raman, M., & Reimer, R. A. (2018) · European Journal of Nutrition · doi:10.1007/s00394-018-1721-2 · Cited by 148
Gut–Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease
Poeta, M., Pierri, L., & Vajro, P. (2017) · Children · doi:10.3390/children4080066 · Cited by 147
Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis
Yu, J., Zhu, C., Wang, X., Kim, K., Bartolome, A., Dongiovanni, P., Yates, K. P., Valenti, L., Carrer, M., Sadowski, T., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe1692 · Cited by 132
Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites
Ding, Y., Yanagi, K., Cheng, C., Alaniz, R. C., Lee, K., & Jayaraman, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.029 · Cited by 125
Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates
Khan, A., Ding, Z., Ishaq, M. H., Bacha, A. S., KHAN, I. A., Hanif, A., Li, W., & Guo, X. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.56214 · Cited by 130
Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis
Li, F., Ye, J., Shao, C., & Zhong, B. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01440-w · Cited by 118
Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis
Liu, X., Sun, R., Li, Z., Xiao, R., Lv, P., Sun, X., Olson, M. A., & Gong, Y. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.109019 · Cited by 115
Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients
Denkmayr, L., Feldman, A., Stechemesser, L., Eder, S. K., Zandanell, S., Schranz, M., Straßer, M., Huber-Schönauer, U., Buch, S., Hampe, J., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120562 · Cited by 116
Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota
Drożdż, K., Nabrdalik, K., Hajzler, W., Kwiendacz, H., Gumprecht, J., & Lip, G. Y. H. (2021) · Nutrients · doi:10.3390/nu14010103 · Cited by 115
Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
Kutlu, Ö., Kaleli, H. N., & Ozer, E. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/8543763 · Cited by 105
Antibiotic pretreatment alleviates liver transplant damage in mice and humans
Nakamura, K., Kageyama, S., Ito, T., Hirao, H., Kadono, K., Aziz, A., Dery, K. J., Everly, M. J., Taura, K., Üemoto, S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127550 · Cited by 98
Inulin Exerts Beneficial Effects on Non-Alcoholic Fatty Liver Disease via Modulating gut Microbiome and Suppressing the Lipopolysaccharide-Toll-Like Receptor 4-Mψ-Nuclear Factor-κB-Nod-Like Receptor Protein 3 Pathway via gut-Liver Axis in Mice
Bao, T., He, F., Zhang, X., Zhu, L., Wang, Z., Lü, H., Wang, T., Li, Y., Yang, S., & Wang, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.558525 · Cited by 92
Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases
Hyun, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179139 · Cited by 87
ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease
Singal, A. K., Wong, R. J., Dasarathy, S., Abdelmalek, M. F., Neuschwander‐Tetri, B. A., Limketkai, B. N., Petrey, J., & McClain, C. J. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003379 · Cited by 93
Hepatic Stellate Cell-Immune Interactions in NASH
Carter, J. K., & Friedman, S. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.867940 · Cited by 79
Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Wiering, L., Subramanian, P., & Hammerich, L. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.02.010 · Cited by 80
Genome-Scale Metabolic Modeling of the Human Microbiome in the Era of Personalized Medicine
Heinken, A., Basile, A., Hertel, J., Thinnes, C. C., & Thiele, I. (2021) · Annual Review of Microbiology · doi:10.1146/annurev-micro-060221-012134 · Cited by 76
Faeces‐derived extracellular vesicles participate in the onset of barrier dysfunction leading to liver diseases
Fizanne, L., Villard, A., Benabbou, N., Recoquillon, S., Soleti, R., Delage, E., Wertheimer, M., Vidal‐Gómez, X., Oullier, T., Chaffron, S., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12303 · Cited by 73
Epigallocatechin Gallate Protects Mice against Methionine–Choline-Deficient-Diet-Induced Nonalcoholic Steatohepatitis by Improving Gut Microbiota To Attenuate Hepatic Injury and Regulate Metabolism
Ning, K., Lu, K., Chen, Q., Guo, Z., Du, X., Riaz, F., Feng, L., Fu, Y., Yin, C., Zhang, F., et al. (2020) · ACS Omega · doi:10.1021/acsomega.0c01689 · Cited by 70
Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies
Wattacheril, J. J., Issa, D., & Sanyal, A. J. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052545 · Cited by 69
Probiotic Bacillus Alleviates Oxidative Stress-Induced Liver Injury by Modulating Gut-Liver Axis in a Rat Model
Wu, Y., Wang, B., Tang, L., Zhou, Y., Wang, Q., Gong, L., Ni, J., & Li, W. (2022) · Antioxidants · doi:10.3390/antiox11020291 · Cited by 71
Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation
Lonardo, A., Mantovani, A., Petta, S., Carraro, A., Byrne, C. D., & Targher, G. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00711-5 · Cited by 69
Approach to the diagnosis and management of dysbiosis
Alagiakrishnan, K., Morgadinho, J., & Halverson, T. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1330903 · Cited by 79
Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?
Jiang, L., & Schnabl, B. (2020) · Physiology · doi:10.1152/physiol.00005.2020 · Cited by 64
Self-citation
Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease
Caenepeel, C., Tabib, N. S. S., Vieira‐Silva, S., & Vermeire, S. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16096 · Cited by 65
Characteristics of gut microbiota in patients with metabolic associated fatty liver disease
Yang, C., Xu, J., Xu, X., Xu, W., Tong, B., Wang, S., Ji, R., Tan, Y. Q., & Zhu, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-37163-4 · Cited by 62
Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis
Schneider, K. M., Mohs, A., Kilic, K., Candels, L. S., Elfers, C., Bennek, E., Schneider, L. B., Heymann, F., Gaßler, N., Penders, J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020308 · Cited by 61
Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis
Takai, A., Kikuchi, K., Ichimura‐Shimizu, M., Tsuneyama, K., Moritoki, Y., Matsumoto, K., Tsunashima, H., Onda, T., Kuniyoshi, N., Nariyama, T., et al. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01194-2 · Cited by 61
Use of probiotics, prebiotics, and synbiotics in non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
Rong, L., Ch’ng, D., Jia, P., Tsoi, K. K. F., Wong, S. H., & Sung, J. J. �. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16256 · Cited by 61
Inhibition of microbial deconjugation of micellar bile acids protects against intestinal permeability and liver injury
Li, D. K., Chaudhari, S. N., Sojoodi, M., Lee, Y., Adhikari, A. A., Zukerberg, L. R., Shroff, S. G., Barrett, S. C., Tanabe, K. K., Chung, R. T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo2794 · Cited by 59
Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis
Wang, M., Li, L., Xu, Y., Du, J., & Ling, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.958428 · Cited by 59
Treating inflammation to combat non-alcoholic fatty liver disease
Wiering, L., & Tacke, F. (2022) · Journal of Endocrinology · doi:10.1530/joe-22-0194 · Cited by 59
Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients
Li, F., Sun, G., Wang, Z., Wu, W., Guo, H., Peng, L., Wu, L., Guo, X., & Yang, Y. (2018) · Science China Life Sciences · doi:10.1007/s11427-017-9303-9 · Cited by 57
Altered gut microbial metabolites could mediate the effects of risk factors in Covid‐19
Chen, J., Hall, S., & Vitetta, L. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2211 · Cited by 55
Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice
Ding, Y., Yanagi, K., Yang, F., Callaway, E. S., Cheng, C., Hensel, M. E., Menon, R., Alaniz, R. C., Lee, K., & Jayaraman, A. (2023) · eLife · doi:10.7554/elife.87458 · Cited by 69
Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH
Jadhav, K. S., & Cohen, T. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.592157 · Cited by 55
Future trends in the treatment of non-alcoholic steatohepatitis
Fiorucci, S., Biagioli, M., & Distrutti, E. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.07.014 · Cited by 53
Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet
Ganguly, S., Muench, G. A., Shang, L., Rosenthal, S. B., Rahman, G., Wang, R., Wang, Y., Kwon, H. C., Diomino, A. M., Kisseleva, T., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.05.010 · Cited by 50
“2021 NASH, HCC, and WD 907 whether intestinal permeability is a cause or consequence of NASH also is debated.(27,28) Therefore, it is important to understand the timeline and kinetics of intestinal permeability in the context of both intestinal and liver inflammation, along with associated dysbiosis.”
BackgroundSelf-citation
Crosstalk between PPARs and gut microbiota in NAFLD
Wu, L., Li, J., Feng, J., Ji, J., Yu, Q., Li, Y., Zheng, Y., Dai, W., Wu, J., & Guo, C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111255 · Cited by 52
Oral Supplementation of Sodium Butyrate Attenuates the Progression of Non-Alcoholic Steatohepatitis
Baumann, A., Jin, C. J., Brandt, A., Sellmann, C., Nier, A., Burkard, M., Venturelli, S., & Bergheim, I. (2020) · Nutrients · doi:10.3390/nu12040951 · Cited by 51
Cruel to Be Kind: Epithelial, Microbial, and Immune Cell Interactions in Gastrointestinal Cancers
Shalapour, S., & Karin, M. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082019-081656 · Cited by 52
Supplementation of a propionate-producing consortium improves markers of insulin resistance in an in vitro model of gut-liver axis
Hage, R. E., Hernandez‐Sanabria, E., Calatayud, M., & de Wiele, T. V. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00523.2019 · Cited by 51
Spatial genomics: mapping human steatotic liver disease
Matchett, K. P., Paris, J., Teichmann, S. A., & Henderson, N. C. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00915-2 · Cited by 53
Gynostemma pentaphyllum polysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2/NLRP3 pathway
Yue, S., Tan, Y.-Y., Zhang, L., Zhang, B., Jiang, F.-Y., Ji, G., Liu, B., & Wang, R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.885039 · Cited by 48
Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
Zhu, B., Chan, S., Li, J., Li, K. S., Wu, H., Cui, K., & Chen, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.742382 · Cited by 47
Antimicrobial proteins: intestinal guards to protect against liver disease
Hendrikx, T., & Schnabl, B. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1521-8 · Cited by 42
Self-citation
Ovariectomy Impaired Hepatic Glucose and Lipid Homeostasis and Altered the Gut Microbiota in Mice With Different Diets
Lei, Z., Wu, H., Yang, Y., Hu, Q. C., Lei, Y., Liu, W., Nie, Y., Yang, L., Zhang, X., Yang, C., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.708838 · Cited by 42
Nonalcoholic fatty liver disease
Sotiropoulou, M. G., Katsaros, I., Vailas, M. G., Lidoriki, I., Papatheodoridis, G., Kostomitsopoulos, N. G., Valsami, G. N., Tsaroucha, A. K., & Schizas, D. (2021) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_249_21 · Cited by 43
Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism
Cornejo-Pareja, I. M., Amiar, M. R., Ocaña-Wilhelmi, L., Soler-Humanes, R., Arranz‐Salas, I., Garrido‐Sánchez, L., Gutiérrez‐Repiso, C., & Tinahones, F. J. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-023-02075-7 · Cited by 40
1-Deoxynojirimycin improves high fat diet-induced nonalcoholic steatohepatitis by restoring gut dysbiosis
Zheng, J., Zhu, L., Hu, B., Zou, X., Hu, H., Zhang, Z., Jiang, N., Ma, J., Yang, H., & Liu, H. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.05.013 · Cited by 41
Emerging concepts in non-invasive monitoring of Crohn’s disease
Marlicz, W. M., Skonieczna‐Żydecka, K., Dabos, K. J., Łoniewski, I., & Koulaouzidis, A. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818769076 · Cited by 38
The Interleukin-20 Cytokine Family in Liver Disease
Caparrós, E., & Francés, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01155 · Cited by 37
Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes
Kriss, M. S., Verna, E. C., Rosen, H. R., & Lozupone, C. (2018) · Transplantation · doi:10.1097/tp.0000000000002568 · Cited by 37
Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease
Fontes, A., Pagès, M. A. I., Oliveira, P. J., Ramalho‐Santos, J., Zischka, H., & Azul, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163987 · Cited by 38
MAIT cells in metabolic diseases
Bertrand, L., & Lehuen, A. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.06.025 · Cited by 34
The contribution of the gut-liver axis to the immune signaling pathway of NAFLD
Liu, J., Wu, A., Cai, J., She, Z., & Li, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968799 · Cited by 42
Citrulline supplementation attenuates the development of non-alcoholic steatohepatitis in female mice through mechanisms involving intestinal arginase
Rajcic, D., Baumann, A., Hernández-Arriaga, A. M., Brandt, A., Nier, A., Jin, C. J., Sánchez, V., Jung, F., Camarinha‐Silva, A., & Bergheim, I. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101879 · Cited by 34
Aqueous extract of Polygala japonica Houtt. ameliorated nonalcoholic steatohepatitis in mice through restoring the gut microbiota disorders and affecting the metabolites in feces and liver
Liao, J., Cao, Y., Zhao, J., Yu, B., Wang, Y., Li, W., Li, H., Lv, S., Wen, W., Cui, H., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154937 · Cited by 34
Exploring a novel therapeutic strategy: the interplay between gut microbiota and high-fat diet in the pathogenesis of metabolic disorders
Jia, X., Chen, Q., Wu, H., Liu, H., Jing, C., Gong, A., & Zhang, Y. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1291853 · Cited by 35
Contributing Roles of CYP2E1 and Other Cytochrome P450 Isoforms in Alcohol-Related Tissue Injury and Carcinogenesis
Song, B., Abdelmegeed, M. A., Cho, Y., Akbar, M. D., Rhim, J. S., Song, M., & Hardwick, J. P. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-22254-3_6 · Cited by 35
Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice
Matsui, M., Fukunishi, S., Nakano, T., Ueno, T., Higuchi, K., & Asai, A. (2021) · mBio · doi:10.1128/mbio.01155-21 · Cited by 35
Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma
Rajesh, Y., & Sarkar, D. (2020) · Cancers · doi:10.3390/cancers12051290 · Cited by 33
Fecal Microbiota Transplantation: Beyond Clostridium difficile
Millan, B., Laffin, M., & Madsen, K. L. (2017) · Current Infectious Disease Reports · doi:10.1007/s11908-017-0586-5 · Cited by 31
Qingrequzhuo capsule alleviated methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice through regulating gut microbiota, enhancing gut tight junction and inhibiting the activation of TLR4/NF-κB signaling pathway
Lv, S., Zhang, Z., Su, X., Li, W., Wang, X., Pan, B., Li, H., Zhang, H., & Wang, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1106875 · Cited by 30
Pathogenesis of NASH and Promising Natural Products
Leng, Y., Zhang, M., Luo, J., & Zhang, H. (2021) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(21)60002-x · Cited by 29
Hepatoprotection of capsaicin in alcoholic and non-alcoholic fatty liver diseases
Karimi‐Sales, E., Mohaddes, G., & Alipour, M. R. (2021) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2021.1962913 · Cited by 28
Exploring the interplay of gut microbiota, inflammation, and LDL-cholesterol: a multiomics Mendelian randomization analysis of their causal relationship in acute pancreatitis and non-alcoholic fatty liver disease
Yan, C., Bao, J., & Jin, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04996-0 · Cited by 33
Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation
Maurice, J. B., Garvey, L. J., Tsochatzis, E. A., Wiltshire, M., Cooke, G., Guppy, N., McDonald, J. A. K., Marchesi, J. R., Nelson, M. R., Kelleher, P., et al. (2019) · AIDS · doi:10.1097/qad.0000000000002133 · Cited by 26
Emulating the gut–liver axis: Dissecting the microbiome's effect on drug metabolism using multiorgan-on-chip models
Lucchetti, M., Kaminska, M., Aina, K. O., Mosig, A. S., & Wilmes, P. (2021) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2021.03.003 · Cited by 28
Oral Supplementation of Phosphatidylcholine Attenuates the Onset of a Diet-Induced Metabolic Dysfunction–Associated Steatohepatitis in Female C57BL/6J Mice
Sánchez, V., Baumann, A., Brandt, A., Wodak, M. F., Staltner, R., & Bergheim, I. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.01.009 · Cited by 25
Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy
Guney-Coskun, M., & Başaranoğlu, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i43.4682 · Cited by 24
FXR agonists INT ‐787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet‐induced ob/ob mouse model of NASH
Pasqua, L. G. D., Cagna, M., Palladini, G., Croce, A. C., Cadamuro, M., Fabris, L., Perlini, S., Adorini, L., Ferrigno, A., & Vairetti, M. (2023) · Liver International · doi:10.1111/liv.15767 · Cited by 24
Hígado graso no alcohólico: una pandemia poco conocida
Augustín, S., Graupera, I., & Caballería, J. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.06.026 · Cited by 23
Mechanism and Therapeutic Targets of c-Jun-N-Terminal Kinases Activation in Nonalcoholic Fatty Liver Disease
Min, R. W. M., Aung, F. W. M., Liu, B., Arya, A., & Win, S. (2022) · Biomedicines · doi:10.3390/biomedicines10082035 · Cited by 22
Deciphering the role of gut metabolites in non-alcoholic fatty liver disease
Ralli, T., Saifi, Z., Tyagi, N., Vidyadhari, A., Aeri, V., & Kohli, K. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2142091 · Cited by 22
Marked gut microbiota dysbiosis and increased imidazole propionate are associated with a NASH Göttingen Minipig model
Lützhøft, D. O., Sinioja, T., Christoffersen, B. Ø., Jakobsen, R. R., Geng, D., Ahmad, H. F., Straarup, E. M., Pedersen, K., Kot, W., Pedersen, H. D., et al. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02704-w · Cited by 23
Links between gut microbiome, metabolome, clinical variables and non‐alcoholic fatty liver disease severity in bariatric patients
Schwenger, K. J. P., Sharma, D., Ghorbani, Y., Xu, W., Lou, W. Y. W., Comelli, E. M., Fischer, S. E., Jackson, T. D., Okrainec, A., & Allard, J. P. (2024) · Liver International · doi:10.1111/liv.15864 · Cited by 22
Hepatic Failure After Bariatric Surgery: A Systematic Review
Keleidari, B., Mahmoudieh, M., Gorgi, K., Sheikhbahaei, E., & Shahmiri, S. S. (2019) · Hepatitis Monthly · doi:10.5812/hepatmon.86078 · Cited by 19
Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug
Guo, J., Xu, Y., Chen, L., Zhang, S.-X., Liou, Y., Chen, X., Tan, Z., Zhou, H., Zhang, W., & Chen, Y. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.10.004 · Cited by 20
The Role of Non-Alcoholic Fatty Liver Disease in Infections
Krznarić, J., & Vince, A. (2022) · Life · doi:10.3390/life12122052 · Cited by 19
Innate immunity and nonalcoholic fatty liver disease
Kountouras, J. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0793 · Cited by 19
Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
Sayıner, M., Lam, B. P., Golabi, P., & Younossi, Z. M. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818811508 · Cited by 20
Characterization of gut dominant microbiota in obese patients with nonalcoholic fatty liver disease
Jin, L.-T., & Xu, M.-Z. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1113643 · Cited by 18
Mitigating Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): The Role of Bioactive Phytoconstituents in Indian Culinary Spices
Barbhuiya, P. A., Ahmed, A., Dutta, P. P., Sen, S., & Pathak, M. P. (2025) · Current Nutrition Reports · doi:10.1007/s13668-024-00598-w · Cited by 18
Disruption of Tumor Suppressors HNF4α/HNF1α Causes Tumorigenesis in Liver
Teeli, A. S., Łuczyńska, K., Haque, E., Gayas, M. A., Winiarczyk, D., & Taniguchi, H. (2021) · Cancers · doi:10.3390/cancers13215357 · Cited by 16

Authors: Brandl, K., & Schnabl, B.
Affiliations: University of California San Diego (US)
Corresponding author: Schnabl, Bernd
ORCID: Brandl, Katharina
Schnabl, Bernd
Venue: Current Opinion in Gastroenterology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2017-05
Volume: 33
Issue: 3
Pages: 128-133
ISSN: 0267-1379 (ISSN-L)
DOI: 10.1097/mog.0000000000000349
PMC: PMC5662009
OpenAlex: W2593189168
Cited by: 169
References: 42
Citations by year: 2026: 3 · 2025: 9 · 2024: 17 · 2023: 25 · 2022: 24 · 2021: 32 · 2020: 20 · 2019: 15 · 2018: 18 · 2017: 6
FWCI: 1.51
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Current Opinion in Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: U.S. Department of Veterans Affairs (I01BX002213)
National Institute on Alcohol Abuse and Alcoholism (R01AA020703, U01AA024726, U01AA021856)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords: nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, gut microbiota, gut dysbiosis, gut-liver axis, intestinal inflammation, intestinal barrier, liver inflammation, metabolomics, metabolomic biomarkers, ethanol, microbiota-based therapy
MeSH terms: Gastrointestinal Microbiome, Humans, Disease Progression, Bacterial Translocation, Metabolomics, Dysbiosis, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intestinal microbiota and nonalcoholic steatohepatitis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks